#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Altered resting-state functional connectivity of the cerebellum in schizophrenia Structural and functional abnormalities of the cerebellum in schizophrenia have been reported.
1-1	0-7	Altered	_
1-2	8-21	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-3	22-32	functional	_
1-4	33-45	connectivity	_
1-5	46-48	of	_
1-6	49-52	the	_
1-7	53-63	cerebellum	_
1-8	64-66	in	_
1-9	67-80	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-10	81-91	Structural	_
1-11	92-95	and	_
1-12	96-106	functional	_
1-13	107-120	abnormalities	_
1-14	121-123	of	_
1-15	124-127	the	_
1-16	128-138	cerebellum	_
1-17	139-141	in	_
1-18	142-155	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-19	156-160	have	_
1-20	161-165	been	_
1-21	166-174	reported	_
1-22	175-176	.	_

Text=Most previous studies investigating resting-state functional connectivity (rsFC) have relied on a priori restrictions on seed regions or specific networks, which may bias observations.
2-1	177-181	Most	_
2-2	182-190	previous	_
2-3	191-198	studies	_
2-4	199-212	investigating	_
2-5	213-226	resting-state	_
2-6	227-237	functional	_
2-7	238-250	connectivity	_
2-8	251-252	(	_
2-9	253-257	rsFC	_
2-10	258-259	)	_
2-11	260-264	have	_
2-12	265-271	relied	_
2-13	272-274	on	_
2-14	275-276	a	_
2-15	277-283	priori	_
2-16	284-296	restrictions	_
2-17	297-299	on	_
2-18	300-304	seed	_
2-19	305-312	regions	_
2-20	313-315	or	_
2-21	316-324	specific	_
2-22	325-333	networks	_
2-23	334-335	,	_
2-24	336-341	which	_
2-25	342-345	may	_
2-26	346-350	bias	_
2-27	351-363	observations	_
2-28	364-365	.	_

Text=In this study, we aimed to elicit the connectivity alterations of the cerebellum in schizophrenia in a hypothesis-free approach.
3-1	366-368	In	_
3-2	369-373	this	_
3-3	374-379	study	_
3-4	380-381	,	_
3-5	382-384	we	_
3-6	385-390	aimed	_
3-7	391-393	to	_
3-8	394-400	elicit	_
3-9	401-404	the	_
3-10	405-417	connectivity	_
3-11	418-429	alterations	_
3-12	430-432	of	_
3-13	433-436	the	_
3-14	437-447	cerebellum	_
3-15	448-450	in	_
3-16	451-464	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-17	465-467	in	_
3-18	468-469	a	_
3-19	470-485	hypothesis-free	_
3-20	486-494	approach	_
3-21	495-496	.	_

Text=Ninety-five schizophrenia patients and 93 sex- and age-matched healthy controls underwent resting-state functional magnetic resonance imaging (fMRI).
4-1	497-508	Ninety-five	_
4-2	509-522	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-3	523-531	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-4	532-535	and	_
4-5	536-538	93	_
4-6	539-543	sex-	_
4-7	544-547	and	_
4-8	548-559	age-matched	_
4-9	560-567	healthy	_
4-10	568-576	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-11	577-586	underwent	_
4-12	587-600	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-13	601-611	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-14	612-620	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-15	621-630	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-16	631-638	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-17	639-640	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-18	641-645	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-19	646-647	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-20	648-649	.	_

Text=A voxel-wise data-driven method, resting-state functional connectivity density (rsFCD), was used to investigate cerebellar connectivity changes in schizophrenia patients.
5-1	650-651	A	_
5-2	652-662	voxel-wise	_
5-3	663-674	data-driven	_
5-4	675-681	method	_
5-5	682-683	,	_
5-6	684-697	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-7	698-708	functional	_
5-8	709-721	connectivity	_
5-9	722-729	density	_
5-10	730-731	(	_
5-11	732-737	rsFCD	_
5-12	738-739	)	_
5-13	740-741	,	_
5-14	742-745	was	_
5-15	746-750	used	_
5-16	751-753	to	_
5-17	754-765	investigate	_
5-18	766-776	cerebellar	_
5-19	777-789	connectivity	_
5-20	790-797	changes	_
5-21	798-800	in	_
5-22	801-814	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-23	815-823	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-24	824-825	.	_

Text=Regions with altered rsFCD were chosen as seeds to perform seed-based resting-state functional connectivity (rsFC) analyses.
6-1	826-833	Regions	_
6-2	834-838	with	_
6-3	839-846	altered	_
6-4	847-852	rsFCD	_
6-5	853-857	were	_
6-6	858-864	chosen	_
6-7	865-867	as	_
6-8	868-873	seeds	_
6-9	874-876	to	_
6-10	877-884	perform	_
6-11	885-895	seed-based	_
6-12	896-909	resting-state	_
6-13	910-920	functional	_
6-14	921-933	connectivity	_
6-15	934-935	(	_
6-16	936-940	rsFC	_
6-17	941-942	)	_
6-18	943-951	analyses	_
6-19	952-953	.	_

Text=We found that schizophrenia patients exhibited decreased rsFCD in the right hemispheric VI; moreover, this cerebellar region showed increased rsFC with the prefrontal cortex and subcortical nuclei and decreased rsFC with the visual cortex and sensorimotor cortex.
7-1	954-956	We	_
7-2	957-962	found	_
7-3	963-967	that	_
7-4	968-981	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-5	982-990	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-6	991-1000	exhibited	_
7-7	1001-1010	decreased	_
7-8	1011-1016	rsFCD	_
7-9	1017-1019	in	_
7-10	1020-1023	the	_
7-11	1024-1029	right	_
7-12	1030-1041	hemispheric	_
7-13	1042-1044	VI	_
7-14	1045-1046	;	_
7-15	1047-1055	moreover	_
7-16	1056-1057	,	_
7-17	1058-1062	this	_
7-18	1063-1073	cerebellar	_
7-19	1074-1080	region	_
7-20	1081-1087	showed	_
7-21	1088-1097	increased	_
7-22	1098-1102	rsFC	_
7-23	1103-1107	with	_
7-24	1108-1111	the	_
7-25	1112-1122	prefrontal	_
7-26	1123-1129	cortex	_
7-27	1130-1133	and	_
7-28	1134-1145	subcortical	_
7-29	1146-1152	nuclei	_
7-30	1153-1156	and	_
7-31	1157-1166	decreased	_
7-32	1167-1171	rsFC	_
7-33	1172-1176	with	_
7-34	1177-1180	the	_
7-35	1181-1187	visual	_
7-36	1188-1194	cortex	_
7-37	1195-1198	and	_
7-38	1199-1211	sensorimotor	_
7-39	1212-1218	cortex	_
7-40	1219-1220	.	_

Text=In addition, some rsFC changes were associated with positive symptoms.
8-1	1221-1223	In	_
8-2	1224-1232	addition	_
8-3	1233-1234	,	_
8-4	1235-1239	some	_
8-5	1240-1244	rsFC	_
8-6	1245-1252	changes	_
8-7	1253-1257	were	_
8-8	1258-1268	associated	_
8-9	1269-1273	with	_
8-10	1274-1282	positive	_
8-11	1283-1291	symptoms	_
8-12	1292-1293	.	_

Text=These findings suggest that abnormalities of the cerebellar hub and cerebellar-subcortical-cortical loop may be the underlying mechanisms of schizophrenia.
9-1	1294-1299	These	_
9-2	1300-1308	findings	_
9-3	1309-1316	suggest	_
9-4	1317-1321	that	_
9-5	1322-1335	abnormalities	_
9-6	1336-1338	of	_
9-7	1339-1342	the	_
9-8	1343-1353	cerebellar	_
9-9	1354-1357	hub	_
9-10	1358-1361	and	_
9-11	1362-1393	cerebellar-subcortical-cortical	_
9-12	1394-1398	loop	_
9-13	1399-1402	may	_
9-14	1403-1405	be	_
9-15	1406-1409	the	_
9-16	1410-1420	underlying	_
9-17	1421-1431	mechanisms	_
9-18	1432-1434	of	_
9-19	1435-1448	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-20	1449-1450	.	_

Text=Materials and methods Subjects Two hundred right-handed individuals were enrolled in this study, including 98 schizophrenia patients and 102 healthy controls.
10-1	1451-1460	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1461-1464	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1465-1472	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1473-1481	Subjects	_
10-5	1482-1485	Two	_
10-6	1486-1493	hundred	_
10-7	1494-1506	right-handed	_
10-8	1507-1518	individuals	_
10-9	1519-1523	were	_
10-10	1524-1532	enrolled	_
10-11	1533-1535	in	_
10-12	1536-1540	this	_
10-13	1541-1546	study	_
10-14	1547-1548	,	_
10-15	1549-1558	including	_
10-16	1559-1561	98	_
10-17	1562-1575	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-18	1576-1584	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-19	1585-1588	and	_
10-20	1589-1592	102	_
10-21	1593-1600	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-22	1601-1609	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-23	1610-1611	.	_

Text=The Medical Research Ethics Committee of Tianjin Medical University General Hospital approved this study.
11-1	1612-1615	The	_
11-2	1616-1623	Medical	_
11-3	1624-1632	Research	_
11-4	1633-1639	Ethics	_
11-5	1640-1649	Committee	_
11-6	1650-1652	of	_
11-7	1653-1660	Tianjin	_
11-8	1661-1668	Medical	_
11-9	1669-1679	University	_
11-10	1680-1687	General	_
11-11	1688-1696	Hospital	_
11-12	1697-1705	approved	_
11-13	1706-1710	this	_
11-14	1711-1716	study	_
11-15	1717-1718	.	_

Text=After a complete description of the study, written informed consent was obtained from each subject.
12-1	1719-1724	After	_
12-2	1725-1726	a	_
12-3	1727-1735	complete	_
12-4	1736-1747	description	_
12-5	1748-1750	of	_
12-6	1751-1754	the	_
12-7	1755-1760	study	_
12-8	1761-1762	,	_
12-9	1763-1770	written	_
12-10	1771-1779	informed	_
12-11	1780-1787	consent	_
12-12	1788-1791	was	_
12-13	1792-1800	obtained	_
12-14	1801-1805	from	_
12-15	1806-1810	each	_
12-16	1811-1818	subject	_
12-17	1819-1820	.	_

Text=The diagnosis of schizophrenia was determined by the consensus of two experienced clinical psychiatrists using the Structured Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P).
13-1	1821-1824	The	_
13-2	1825-1834	diagnosis	_
13-3	1835-1837	of	_
13-4	1838-1851	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-5	1852-1855	was	_
13-6	1856-1866	determined	_
13-7	1867-1869	by	_
13-8	1870-1873	the	_
13-9	1874-1883	consensus	_
13-10	1884-1886	of	_
13-11	1887-1890	two	_
13-12	1891-1902	experienced	_
13-13	1903-1911	clinical	_
13-14	1912-1925	psychiatrists	_
13-15	1926-1931	using	_
13-16	1932-1935	the	_
13-17	1936-1946	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-18	1947-1956	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-19	1957-1960	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-20	1961-1967	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-21	1968-1972	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-22	1973-1974	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-23	1975-1984	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
13-24	1985-1986	,	_
13-25	1987-1994	Patient	_
13-26	1995-2002	Edition	_
13-27	2003-2004	(	_
13-28	2005-2011	SCID-P	_
13-29	2012-2013	)	_
13-30	2014-2015	.	_

Text=Healthy controls were recruited from the local community via advertisements.
14-1	2016-2023	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-2	2024-2032	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-3	2033-2037	were	_
14-4	2038-2047	recruited	_
14-5	2048-2052	from	_
14-6	2053-2056	the	_
14-7	2057-2062	local	_
14-8	2063-2072	community	_
14-9	2073-2076	via	_
14-10	2077-2091	advertisements	_
14-11	2092-2093	.	_

Text=All healthy controls were screened using the non-patient edition of the SCID (SCID-NP) to confirm a lifetime absence of psychiatric illnesses.
15-1	2094-2097	All	_
15-2	2098-2105	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-3	2106-2114	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-4	2115-2119	were	_
15-5	2120-2128	screened	_
15-6	2129-2134	using	_
15-7	2135-2138	the	_
15-8	2139-2150	non-patient	_
15-9	2151-2158	edition	_
15-10	2159-2161	of	_
15-11	2162-2165	the	_
15-12	2166-2170	SCID	_
15-13	2171-2172	(	_
15-14	2173-2180	SCID-NP	_
15-15	2181-2182	)	_
15-16	2183-2185	to	_
15-17	2186-2193	confirm	_
15-18	2194-2195	a	_
15-19	2196-2204	lifetime	_
15-20	2205-2212	absence	_
15-21	2213-2215	of	_
15-22	2216-2227	psychiatric	_
15-23	2228-2237	illnesses	_
15-24	2238-2239	.	_

Text=In addition, all of the healthy controls were interviewed to exclude individuals with a known history of psychiatric illness in first-degree relatives.
16-1	2240-2242	In	_
16-2	2243-2251	addition	_
16-3	2252-2253	,	_
16-4	2254-2257	all	_
16-5	2258-2260	of	_
16-6	2261-2264	the	_
16-7	2265-2272	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-8	2273-2281	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-9	2282-2286	were	_
16-10	2287-2298	interviewed	_
16-11	2299-2301	to	_
16-12	2302-2309	exclude	_
16-13	2310-2321	individuals	_
16-14	2322-2326	with	_
16-15	2327-2328	a	_
16-16	2329-2334	known	_
16-17	2335-2342	history	_
16-18	2343-2345	of	_
16-19	2346-2357	psychiatric	_
16-20	2358-2365	illness	_
16-21	2366-2368	in	_
16-22	2369-2381	first-degree	_
16-23	2382-2391	relatives	_
16-24	2392-2393	.	_

Text=The exclusion criteria for all subjects were MRI contraindications, a history of head trauma with consciousness disturbances lasting more than five minutes, a history of drug or alcohol abuse, pregnancy, and any physical illness such as cardiovascular disease or neurological disorders, as diagnosed by an interview and medical records review.
17-1	2394-2397	The	_
17-2	2398-2407	exclusion	_
17-3	2408-2416	criteria	_
17-4	2417-2420	for	_
17-5	2421-2424	all	_
17-6	2425-2433	subjects	_
17-7	2434-2438	were	_
17-8	2439-2442	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
17-9	2443-2460	contraindications	_
17-10	2461-2462	,	_
17-11	2463-2464	a	_
17-12	2465-2472	history	_
17-13	2473-2475	of	_
17-14	2476-2480	head	_
17-15	2481-2487	trauma	_
17-16	2488-2492	with	_
17-17	2493-2506	consciousness	_
17-18	2507-2519	disturbances	_
17-19	2520-2527	lasting	_
17-20	2528-2532	more	_
17-21	2533-2537	than	_
17-22	2538-2542	five	_
17-23	2543-2550	minutes	_
17-24	2551-2552	,	_
17-25	2553-2554	a	_
17-26	2555-2562	history	_
17-27	2563-2565	of	_
17-28	2566-2570	drug	_
17-29	2571-2573	or	_
17-30	2574-2581	alcohol	_
17-31	2582-2587	abuse	_
17-32	2588-2589	,	_
17-33	2590-2599	pregnancy	_
17-34	2600-2601	,	_
17-35	2602-2605	and	_
17-36	2606-2609	any	_
17-37	2610-2618	physical	_
17-38	2619-2626	illness	_
17-39	2627-2631	such	_
17-40	2632-2634	as	_
17-41	2635-2649	cardiovascular	_
17-42	2650-2657	disease	_
17-43	2658-2660	or	_
17-44	2661-2673	neurological	_
17-45	2674-2683	disorders	_
17-46	2684-2685	,	_
17-47	2686-2688	as	_
17-48	2689-2698	diagnosed	_
17-49	2699-2701	by	_
17-50	2702-2704	an	_
17-51	2705-2714	interview	_
17-52	2715-2718	and	_
17-53	2719-2726	medical	_
17-54	2727-2734	records	_
17-55	2735-2741	review	_
17-56	2742-2743	.	_

Text=A professional radiologist assessed the image quality slice-by-slice, and three patients and 9 healthy controls with poor image quality were excluded.
18-1	2744-2745	A	_
18-2	2746-2758	professional	_
18-3	2759-2770	radiologist	_
18-4	2771-2779	assessed	_
18-5	2780-2783	the	_
18-6	2784-2789	image	_
18-7	2790-2797	quality	_
18-8	2798-2812	slice-by-slice	_
18-9	2813-2814	,	_
18-10	2815-2818	and	_
18-11	2819-2824	three	_
18-12	2825-2833	patients	_
18-13	2834-2837	and	_
18-14	2838-2839	9	_
18-15	2840-2847	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-16	2848-2856	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-17	2857-2861	with	_
18-18	2862-2866	poor	_
18-19	2867-2872	image	_
18-20	2873-2880	quality	_
18-21	2881-2885	were	_
18-22	2886-2894	excluded	_
18-23	2895-2896	.	_

Text=Consequently, 95 schizophrenia patients and 93 healthy controls were included in the statistical analysis.
19-1	2897-2909	Consequently	_
19-2	2910-2911	,	_
19-3	2912-2914	95	_
19-4	2915-2928	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-5	2929-2937	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-6	2938-2941	and	_
19-7	2942-2944	93	_
19-8	2945-2952	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-9	2953-2961	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-10	2962-2966	were	_
19-11	2967-2975	included	_
19-12	2976-2978	in	_
19-13	2979-2982	the	_
19-14	2983-2994	statistical	_
19-15	2995-3003	analysis	_
19-16	3004-3005	.	_

Text=The clinical symptoms of psychosis were quantified using the Positive and Negative Syndrome Scale (PANSS).
20-1	3006-3009	The	_
20-2	3010-3018	clinical	_
20-3	3019-3027	symptoms	_
20-4	3028-3030	of	_
20-5	3031-3040	psychosis	_
20-6	3041-3045	were	_
20-7	3046-3056	quantified	_
20-8	3057-3062	using	_
20-9	3063-3066	the	_
20-10	3067-3075	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-11	3076-3079	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-12	3080-3088	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-13	3089-3097	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-14	3098-3103	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-15	3104-3105	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-16	3106-3111	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-17	3112-3113	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-18	3114-3115	.	_

Text=The antipsychotic dosages are reported as the chlorpromazine equivalents calculated based on clinically equivalent dosing estimates (Gardner et al .).
21-1	3116-3119	The	_
21-2	3120-3133	antipsychotic	_
21-3	3134-3141	dosages	_
21-4	3142-3145	are	_
21-5	3146-3154	reported	_
21-6	3155-3157	as	_
21-7	3158-3161	the	_
21-8	3162-3176	chlorpromazine	_
21-9	3177-3188	equivalents	_
21-10	3189-3199	calculated	_
21-11	3200-3205	based	_
21-12	3206-3208	on	_
21-13	3209-3219	clinically	_
21-14	3220-3230	equivalent	_
21-15	3231-3237	dosing	_
21-16	3238-3247	estimates	_
21-17	3248-3249	(	_
21-18	3250-3257	Gardner	_
21-19	3258-3260	et	_
21-20	3261-3263	al	_
21-21	3264-3265	.	_
21-22	3266-3267	)	_
21-23	3268-3269	.	_

Text=For each schizophrenia patient, the chlorpromazine equivalent was estimated according to the antipsychotic drugs and dosages used in the latest week before MRI.
22-1	3270-3273	For	_
22-2	3274-3278	each	_
22-3	3279-3292	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-4	3293-3300	patient	_
22-5	3301-3302	,	_
22-6	3303-3306	the	_
22-7	3307-3321	chlorpromazine	_
22-8	3322-3332	equivalent	_
22-9	3333-3336	was	_
22-10	3337-3346	estimated	_
22-11	3347-3356	according	_
22-12	3357-3359	to	_
22-13	3360-3363	the	_
22-14	3364-3377	antipsychotic	_
22-15	3378-3383	drugs	_
22-16	3384-3387	and	_
22-17	3388-3395	dosages	_
22-18	3396-3400	used	_
22-19	3401-3403	in	_
22-20	3404-3407	the	_
22-21	3408-3414	latest	_
22-22	3415-3419	week	_
22-23	3420-3426	before	_
22-24	3427-3430	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
22-25	3431-3432	.	_

Text=MRI data acquisition MRI data were acquired using a 3.0-Tesla MR system (Discovery MR750, General Electric, Milwaukee, WI, USA).
23-1	3433-3436	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-2	3437-3441	data	_
23-3	3442-3453	acquisition	_
23-4	3454-3457	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-5	3458-3462	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-6	3463-3467	were	_
23-7	3468-3476	acquired	_
23-8	3477-3482	using	_
23-9	3483-3484	a	_
23-10	3485-3494	3.0-Tesla	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
23-11	3495-3497	MR	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
23-12	3498-3504	system	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
23-13	3505-3506	(	_
23-14	3507-3516	Discovery	_
23-15	3517-3522	MR750	_
23-16	3523-3524	,	_
23-17	3525-3532	General	_
23-18	3533-3541	Electric	_
23-19	3542-3543	,	_
23-20	3544-3553	Milwaukee	_
23-21	3554-3555	,	_
23-22	3556-3558	WI	_
23-23	3559-3560	,	_
23-24	3561-3564	USA	_
23-25	3565-3566	)	_
23-26	3567-3568	.	_

Text=Tight but comfortable foam padding was used to minimize head motion, and earplugs were used to reduce scanner noise.
24-1	3569-3574	Tight	_
24-2	3575-3578	but	_
24-3	3579-3590	comfortable	_
24-4	3591-3595	foam	_
24-5	3596-3603	padding	_
24-6	3604-3607	was	_
24-7	3608-3612	used	_
24-8	3613-3615	to	_
24-9	3616-3624	minimize	_
24-10	3625-3629	head	_
24-11	3630-3636	motion	_
24-12	3637-3638	,	_
24-13	3639-3642	and	_
24-14	3643-3651	earplugs	_
24-15	3652-3656	were	_
24-16	3657-3661	used	_
24-17	3662-3664	to	_
24-18	3665-3671	reduce	_
24-19	3672-3679	scanner	_
24-20	3680-3685	noise	_
24-21	3686-3687	.	_

Text=Sagittal 3D T1-weighted images were acquired using a brain volume sequence and the following parameters: repetition time (TR) = 8.2 ms; echo time (TE) = 3.2 ms; inversion time (TI) = 450 ms; flip angle (FA) = 12°; field of view (FOV) = 256 mm × 256 mm; matrix =256 × 256; slice thickness = 1 mm, no gap; and 188 sagittal slices.
25-1	3688-3696	Sagittal	http://maven.renci.org/NeuroBridge/neurobridge#DigitalScale
25-2	3697-3699	3D	http://maven.renci.org/NeuroBridge/neurobridge#DigitalScale
25-3	3700-3711	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-4	3712-3718	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
25-5	3719-3723	were	_
25-6	3724-3732	acquired	_
25-7	3733-3738	using	_
25-8	3739-3740	a	_
25-9	3741-3746	brain	_
25-10	3747-3753	volume	_
25-11	3754-3762	sequence	_
25-12	3763-3766	and	_
25-13	3767-3770	the	_
25-14	3771-3780	following	_
25-15	3781-3791	parameters	_
25-16	3792-3793	:	_
25-17	3794-3804	repetition	_
25-18	3805-3809	time	_
25-19	3810-3811	(	_
25-20	3812-3814	TR	_
25-21	3815-3816	)	_
25-22	3817-3818	=	_
25-23	3819-3822	8.2	_
25-24	3823-3825	ms	_
25-25	3826-3827	;	_
25-26	3828-3832	echo	_
25-27	3833-3837	time	_
25-28	3838-3839	(	_
25-29	3840-3842	TE	_
25-30	3843-3844	)	_
25-31	3845-3846	=	_
25-32	3847-3850	3.2	_
25-33	3851-3853	ms	_
25-34	3854-3855	;	_
25-35	3856-3865	inversion	_
25-36	3866-3870	time	_
25-37	3871-3872	(	_
25-38	3873-3875	TI	_
25-39	3876-3877	)	_
25-40	3878-3879	=	_
25-41	3880-3883	450	_
25-42	3884-3886	ms	_
25-43	3887-3888	;	_
25-44	3889-3893	flip	_
25-45	3894-3899	angle	_
25-46	3900-3901	(	_
25-47	3902-3904	FA	_
25-48	3905-3906	)	_
25-49	3907-3908	=	_
25-50	3909-3912	12°	_
25-51	3913-3914	;	_
25-52	3915-3920	field	_
25-53	3921-3923	of	_
25-54	3924-3928	view	_
25-55	3929-3930	(	_
25-56	3931-3934	FOV	_
25-57	3935-3936	)	_
25-58	3937-3938	=	_
25-59	3939-3942	256	_
25-60	3943-3945	mm	_
25-61	3946-3947	×	_
25-62	3948-3951	256	_
25-63	3952-3954	mm	_
25-64	3955-3956	;	_
25-65	3957-3963	matrix	_
25-66	3964-3968	=256	_
25-67	3969-3970	×	_
25-68	3971-3974	256	_
25-69	3975-3976	;	_
25-70	3977-3982	slice	_
25-71	3983-3992	thickness	_
25-72	3993-3994	=	_
25-73	3995-3996	1	_
25-74	3997-3999	mm	_
25-75	4000-4001	,	_
25-76	4002-4004	no	_
25-77	4005-4008	gap	_
25-78	4009-4010	;	_
25-79	4011-4014	and	_
25-80	4015-4018	188	_
25-81	4019-4027	sagittal	_
25-82	4028-4034	slices	_
25-83	4035-4036	.	_

Text=Resting-state fMRI data were acquired using a gradient-echo single-short echo planar imaging sequence with the following parameters: TR/TE = 2000/45 ms; FOV = 220 mm × 220 mm; matrix =64 × 64; FA = 90°; slice thickness = 4 mm; gap =0.5 mm; 32 interleaved transverse slices; and 180 volumes.
26-1	4037-4050	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
26-2	4051-4055	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
26-3	4056-4060	data	_
26-4	4061-4065	were	_
26-5	4066-4074	acquired	_
26-6	4075-4080	using	_
26-7	4081-4082	a	_
26-8	4083-4096	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-9	4097-4109	single-short	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-10	4110-4114	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-11	4115-4121	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-12	4122-4129	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-13	4130-4138	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-14	4139-4143	with	_
26-15	4144-4147	the	_
26-16	4148-4157	following	_
26-17	4158-4168	parameters	_
26-18	4169-4170	:	_
26-19	4171-4176	TR/TE	_
26-20	4177-4178	=	_
26-21	4179-4186	2000/45	_
26-22	4187-4189	ms	_
26-23	4190-4191	;	_
26-24	4192-4195	FOV	_
26-25	4196-4197	=	_
26-26	4198-4201	220	_
26-27	4202-4204	mm	_
26-28	4205-4206	×	_
26-29	4207-4210	220	_
26-30	4211-4213	mm	_
26-31	4214-4215	;	_
26-32	4216-4222	matrix	_
26-33	4223-4226	=64	_
26-34	4227-4228	×	_
26-35	4229-4231	64	_
26-36	4232-4233	;	_
26-37	4234-4236	FA	_
26-38	4237-4238	=	_
26-39	4239-4242	90°	_
26-40	4243-4244	;	_
26-41	4245-4250	slice	_
26-42	4251-4260	thickness	_
26-43	4261-4262	=	_
26-44	4263-4264	4	_
26-45	4265-4267	mm	_
26-46	4268-4269	;	_
26-47	4270-4273	gap	_
26-48	4274-4278	=0.5	_
26-49	4279-4281	mm	_
26-50	4282-4283	;	_
26-51	4284-4286	32	_
26-52	4287-4298	interleaved	_
26-53	4299-4309	transverse	_
26-54	4310-4316	slices	_
26-55	4317-4318	;	_
26-56	4319-4322	and	_
26-57	4323-4326	180	_
26-58	4327-4334	volumes	_
26-59	4335-4336	.	_

Text=All subjects were instructed to keep their eyes closed, relax, move as little as possible, think of nothing in particular, and not fall asleep during the fMRI scans.
27-1	4337-4340	All	_
27-2	4341-4349	subjects	_
27-3	4350-4354	were	_
27-4	4355-4365	instructed	_
27-5	4366-4368	to	_
27-6	4369-4373	keep	_
27-7	4374-4379	their	_
27-8	4380-4384	eyes	_
27-9	4385-4391	closed	_
27-10	4392-4393	,	_
27-11	4394-4399	relax	_
27-12	4400-4401	,	_
27-13	4402-4406	move	_
27-14	4407-4409	as	_
27-15	4410-4416	little	_
27-16	4417-4419	as	_
27-17	4420-4428	possible	_
27-18	4429-4430	,	_
27-19	4431-4436	think	_
27-20	4437-4439	of	_
27-21	4440-4447	nothing	_
27-22	4448-4450	in	_
27-23	4451-4461	particular	_
27-24	4462-4463	,	_
27-25	4464-4467	and	_
27-26	4468-4471	not	_
27-27	4472-4476	fall	_
27-28	4477-4483	asleep	_
27-29	4484-4490	during	_
27-30	4491-4494	the	_
27-31	4495-4499	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-32	4500-4505	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-33	4506-4507	.	_

Text=fMRI data preprocessing Resting-state fMRI data were preprocessed using SPM8 (http: //www.fil.ion.ucl.ac.uk/spm).
28-1	4508-4512	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-2	4513-4517	data	_
28-3	4518-4531	preprocessing	_
28-4	4532-4545	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
28-5	4546-4550	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
28-6	4551-4555	data	_
28-7	4556-4560	were	_
28-8	4561-4573	preprocessed	_
28-9	4574-4579	using	_
28-10	4580-4584	SPM8	_
28-11	4585-4586	(	_
28-12	4587-4591	http	_
28-13	4592-4593	:	_
28-14	4594-4621	//www.fil.ion.ucl.ac.uk/spm	_
28-15	4622-4623	)	_
28-16	4624-4625	.	_

Text=The first 10 volumes for each subject were discarded to allow the signal to reach equilibrium and the participants to adapt to the scanning noise.
29-1	4626-4629	The	_
29-2	4630-4635	first	_
29-3	4636-4638	10	_
29-4	4639-4646	volumes	_
29-5	4647-4650	for	_
29-6	4651-4655	each	_
29-7	4656-4663	subject	_
29-8	4664-4668	were	_
29-9	4669-4678	discarded	_
29-10	4679-4681	to	_
29-11	4682-4687	allow	_
29-12	4688-4691	the	_
29-13	4692-4698	signal	_
29-14	4699-4701	to	_
29-15	4702-4707	reach	_
29-16	4708-4719	equilibrium	_
29-17	4720-4723	and	_
29-18	4724-4727	the	_
29-19	4728-4740	participants	_
29-20	4741-4743	to	_
29-21	4744-4749	adapt	_
29-22	4750-4752	to	_
29-23	4753-4756	the	_
29-24	4757-4765	scanning	_
29-25	4766-4771	noise	_
29-26	4772-4773	.	_

Text=The remaining volumes were corrected for the acquisition time delay between slices.
30-1	4774-4777	The	_
30-2	4778-4787	remaining	_
30-3	4788-4795	volumes	_
30-4	4796-4800	were	_
30-5	4801-4810	corrected	_
30-6	4811-4814	for	_
30-7	4815-4818	the	_
30-8	4819-4830	acquisition	_
30-9	4831-4835	time	_
30-10	4836-4841	delay	_
30-11	4842-4849	between	_
30-12	4850-4856	slices	_
30-13	4857-4858	.	_

Text=Next, realignment was performed to correct the motion between time points.
31-1	4859-4863	Next	_
31-2	4864-4865	,	_
31-3	4866-4877	realignment	_
31-4	4878-4881	was	_
31-5	4882-4891	performed	_
31-6	4892-4894	to	_
31-7	4895-4902	correct	_
31-8	4903-4906	the	_
31-9	4907-4913	motion	_
31-10	4914-4921	between	_
31-11	4922-4926	time	_
31-12	4927-4933	points	_
31-13	4934-4935	.	_

Text=All of the subjects ’ fMRI data were within the defined motion thresholds (i.e., translational or rotational motion parameters less than 2 mm or 2°).
32-1	4936-4939	All	_
32-2	4940-4942	of	_
32-3	4943-4946	the	_
32-4	4947-4955	subjects	_
32-5	4956-4957	’	_
32-6	4958-4962	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
32-7	4963-4967	data	_
32-8	4968-4972	were	_
32-9	4973-4979	within	_
32-10	4980-4983	the	_
32-11	4984-4991	defined	_
32-12	4992-4998	motion	_
32-13	4999-5009	thresholds	_
32-14	5010-5011	(	_
32-15	5012-5016	i.e.	_
32-16	5017-5018	,	_
32-17	5019-5032	translational	_
32-18	5033-5035	or	_
32-19	5036-5046	rotational	_
32-20	5047-5053	motion	_
32-21	5054-5064	parameters	_
32-22	5065-5069	less	_
32-23	5070-5074	than	_
32-24	5075-5076	2	_
32-25	5077-5079	mm	_
32-26	5080-5082	or	_
32-27	5083-5085	2°	_
32-28	5086-5087	)	_
32-29	5088-5089	.	_

Text=We also calculated frame-wise displacement (FD), which indexes the volume-to-volume changes in head position.
33-1	5090-5092	We	_
33-2	5093-5097	also	_
33-3	5098-5108	calculated	_
33-4	5109-5119	frame-wise	_
33-5	5120-5132	displacement	_
33-6	5133-5134	(	_
33-7	5135-5137	FD	_
33-8	5138-5139	)	_
33-9	5140-5141	,	_
33-10	5142-5147	which	_
33-11	5148-5155	indexes	_
33-12	5156-5159	the	_
33-13	5160-5176	volume-to-volume	_
33-14	5177-5184	changes	_
33-15	5185-5187	in	_
33-16	5188-5192	head	_
33-17	5193-5201	position	_
33-18	5202-5203	.	_

Text=There were no significant group differences in FD (t = 0.56, P = 0.58) between the patients (0.117 ± 0.007) and controls (0.113 ± 0.006).
34-1	5204-5209	There	_
34-2	5210-5214	were	_
34-3	5215-5217	no	_
34-4	5218-5229	significant	_
34-5	5230-5235	group	_
34-6	5236-5247	differences	_
34-7	5248-5250	in	_
34-8	5251-5253	FD	_
34-9	5254-5255	(	_
34-10	5256-5257	t	_
34-11	5258-5259	=	_
34-12	5260-5264	0.56	_
34-13	5265-5266	,	_
34-14	5267-5268	P	_
34-15	5269-5270	=	_
34-16	5271-5275	0.58	_
34-17	5276-5277	)	_
34-18	5278-5285	between	_
34-19	5286-5289	the	_
34-20	5290-5298	patients	_
34-21	5299-5300	(	_
34-22	5301-5306	0.117	_
34-23	5307-5308	±	_
34-24	5309-5314	0.007	_
34-25	5315-5316	)	_
34-26	5317-5320	and	_
34-27	5321-5329	controls	_
34-28	5330-5331	(	_
34-29	5332-5337	0.113	_
34-30	5338-5339	±	_
34-31	5340-5345	0.006	_
34-32	5346-5347	)	_
34-33	5348-5349	.	_

Text=Several nuisance covariates (six motion parameters, their first-time derivations, and average BOLD signals of the ventricular and white matter) were regressed out from the data.
35-1	5350-5357	Several	_
35-2	5358-5366	nuisance	_
35-3	5367-5377	covariates	_
35-4	5378-5379	(	_
35-5	5380-5383	six	_
35-6	5384-5390	motion	_
35-7	5391-5401	parameters	_
35-8	5402-5403	,	_
35-9	5404-5409	their	_
35-10	5410-5420	first-time	_
35-11	5421-5432	derivations	_
35-12	5433-5434	,	_
35-13	5435-5438	and	_
35-14	5439-5446	average	_
35-15	5447-5451	BOLD	_
35-16	5452-5459	signals	_
35-17	5460-5462	of	_
35-18	5463-5466	the	_
35-19	5467-5478	ventricular	_
35-20	5479-5482	and	_
35-21	5483-5488	white	_
35-22	5489-5495	matter	_
35-23	5496-5497	)	_
35-24	5498-5502	were	_
35-25	5503-5512	regressed	_
35-26	5513-5516	out	_
35-27	5517-5521	from	_
35-28	5522-5525	the	_
35-29	5526-5530	data	_
35-30	5531-5532	.	_

Text=Recent studies have reported that the signal spike caused by head motion significantly contaminated the final resting-state fMRI results even after regressing out the linear motion parameters (Power et al .).
36-1	5533-5539	Recent	_
36-2	5540-5547	studies	_
36-3	5548-5552	have	_
36-4	5553-5561	reported	_
36-5	5562-5566	that	_
36-6	5567-5570	the	_
36-7	5571-5577	signal	_
36-8	5578-5583	spike	_
36-9	5584-5590	caused	_
36-10	5591-5593	by	_
36-11	5594-5598	head	_
36-12	5599-5605	motion	_
36-13	5606-5619	significantly	_
36-14	5620-5632	contaminated	_
36-15	5633-5636	the	_
36-16	5637-5642	final	_
36-17	5643-5656	resting-state	_
36-18	5657-5661	fMRI	_
36-19	5662-5669	results	_
36-20	5670-5674	even	_
36-21	5675-5680	after	_
36-22	5681-5691	regressing	_
36-23	5692-5695	out	_
36-24	5696-5699	the	_
36-25	5700-5706	linear	_
36-26	5707-5713	motion	_
36-27	5714-5724	parameters	_
36-28	5725-5726	(	_
36-29	5727-5732	Power	_
36-30	5733-5735	et	_
36-31	5736-5738	al	_
36-32	5739-5740	.	_
36-33	5741-5742	)	_
36-34	5743-5744	.	_

Text=Therefore, we further regressed out spike volumes when the FD of the specific volume exceeded 0.5.
37-1	5745-5754	Therefore	_
37-2	5755-5756	,	_
37-3	5757-5759	we	_
37-4	5760-5767	further	_
37-5	5768-5777	regressed	_
37-6	5778-5781	out	_
37-7	5782-5787	spike	_
37-8	5788-5795	volumes	_
37-9	5796-5800	when	_
37-10	5801-5804	the	_
37-11	5805-5807	FD	_
37-12	5808-5810	of	_
37-13	5811-5814	the	_
37-14	5815-5823	specific	_
37-15	5824-5830	volume	_
37-16	5831-5839	exceeded	_
37-17	5840-5843	0.5	_
37-18	5844-5845	.	_

Text=The datasets were then band-pass filtered in a frequency range of 0.01 to 0.08 Hz.
38-1	5846-5849	The	_
38-2	5850-5858	datasets	_
38-3	5859-5863	were	_
38-4	5864-5868	then	_
38-5	5869-5878	band-pass	_
38-6	5879-5887	filtered	_
38-7	5888-5890	in	_
38-8	5891-5892	a	_
38-9	5893-5902	frequency	_
38-10	5903-5908	range	_
38-11	5909-5911	of	_
38-12	5912-5916	0.01	_
38-13	5917-5919	to	_
38-14	5920-5924	0.08	_
38-15	5925-5927	Hz	_
38-16	5928-5929	.	_

Text=In the normalization step, individual structural images were linearly co-registered with the mean functional image; the transformed structural images were segmented into gray matter, white matter, and cerebrospinal fluid.
39-1	5930-5932	In	_
39-2	5933-5936	the	_
39-3	5937-5950	normalization	_
39-4	5951-5955	step	_
39-5	5956-5957	,	_
39-6	5958-5968	individual	_
39-7	5969-5979	structural	_
39-8	5980-5986	images	_
39-9	5987-5991	were	_
39-10	5992-6000	linearly	_
39-11	6001-6014	co-registered	_
39-12	6015-6019	with	_
39-13	6020-6023	the	_
39-14	6024-6028	mean	_
39-15	6029-6039	functional	_
39-16	6040-6045	image	_
39-17	6046-6047	;	_
39-18	6048-6051	the	_
39-19	6052-6063	transformed	_
39-20	6064-6074	structural	_
39-21	6075-6081	images	_
39-22	6082-6086	were	_
39-23	6087-6096	segmented	_
39-24	6097-6101	into	_
39-25	6102-6106	gray	_
39-26	6107-6113	matter	_
39-27	6114-6115	,	_
39-28	6116-6121	white	_
39-29	6122-6128	matter	_
39-30	6129-6130	,	_
39-31	6131-6134	and	_
39-32	6135-6148	cerebrospinal	_
39-33	6149-6154	fluid	_
39-34	6155-6156	.	_

Text=The gray matter maps were non-linearly transformed to the tissue probability maps in the Montreal Neurological Institute (MNI) space.
40-1	6157-6160	The	_
40-2	6161-6165	gray	_
40-3	6166-6172	matter	_
40-4	6173-6177	maps	_
40-5	6178-6182	were	_
40-6	6183-6195	non-linearly	_
40-7	6196-6207	transformed	_
40-8	6208-6210	to	_
40-9	6211-6214	the	_
40-10	6215-6221	tissue	_
40-11	6222-6233	probability	_
40-12	6234-6238	maps	_
40-13	6239-6241	in	_
40-14	6242-6245	the	_
40-15	6246-6254	Montreal	_
40-16	6255-6267	Neurological	_
40-17	6268-6277	Institute	_
40-18	6278-6279	(	_
40-19	6280-6283	MNI	_
40-20	6284-6285	)	_
40-21	6286-6291	space	_
40-22	6292-6293	.	_

Text=Finally, each filtered functional volume was spatially normalized to the MNI space using the parameters estimated during the non-linear transformation and resampled into a 3-mm cubic voxel.
41-1	6294-6301	Finally	_
41-2	6302-6303	,	_
41-3	6304-6308	each	_
41-4	6309-6317	filtered	_
41-5	6318-6328	functional	_
41-6	6329-6335	volume	_
41-7	6336-6339	was	_
41-8	6340-6349	spatially	_
41-9	6350-6360	normalized	_
41-10	6361-6363	to	_
41-11	6364-6367	the	_
41-12	6368-6371	MNI	_
41-13	6372-6377	space	_
41-14	6378-6383	using	_
41-15	6384-6387	the	_
41-16	6388-6398	parameters	_
41-17	6399-6408	estimated	_
41-18	6409-6415	during	_
41-19	6416-6419	the	_
41-20	6420-6430	non-linear	_
41-21	6431-6445	transformation	_
41-22	6446-6449	and	_
41-23	6450-6459	resampled	_
41-24	6460-6464	into	_
41-25	6465-6466	a	_
41-26	6467-6471	3-mm	_
41-27	6472-6477	cubic	_
41-28	6478-6483	voxel	_
41-29	6484-6485	.	_

Text=rsFCD calculation and analysis The rsFCD of each voxel was calculated using an in-house script that was written in the Linux platform according to the method described by Tomasi and Volkow (Tomasi and Volkow).
42-1	6486-6491	rsFCD	_
42-2	6492-6503	calculation	_
42-3	6504-6507	and	_
42-4	6508-6516	analysis	_
42-5	6517-6520	The	_
42-6	6521-6526	rsFCD	_
42-7	6527-6529	of	_
42-8	6530-6534	each	_
42-9	6535-6540	voxel	_
42-10	6541-6544	was	_
42-11	6545-6555	calculated	_
42-12	6556-6561	using	_
42-13	6562-6564	an	_
42-14	6565-6573	in-house	_
42-15	6574-6580	script	_
42-16	6581-6585	that	_
42-17	6586-6589	was	_
42-18	6590-6597	written	_
42-19	6598-6600	in	_
42-20	6601-6604	the	_
42-21	6605-6610	Linux	_
42-22	6611-6619	platform	_
42-23	6620-6629	according	_
42-24	6630-6632	to	_
42-25	6633-6636	the	_
42-26	6637-6643	method	_
42-27	6644-6653	described	_
42-28	6654-6656	by	_
42-29	6657-6663	Tomasi	_
42-30	6664-6667	and	_
42-31	6668-6674	Volkow	_
42-32	6675-6676	(	_
42-33	6677-6683	Tomasi	_
42-34	6684-6687	and	_
42-35	6688-6694	Volkow	_
42-36	6695-6696	)	_
42-37	6697-6698	.	_

Text=Pearson ’ s linear correlation evaluated the strength of the functional connectivity between every pair of voxels in the entire brain.
43-1	6699-6706	Pearson	_
43-2	6707-6708	’	_
43-3	6709-6710	s	_
43-4	6711-6717	linear	_
43-5	6718-6729	correlation	_
43-6	6730-6739	evaluated	_
43-7	6740-6743	the	_
43-8	6744-6752	strength	_
43-9	6753-6755	of	_
43-10	6756-6759	the	_
43-11	6760-6770	functional	_
43-12	6771-6783	connectivity	_
43-13	6784-6791	between	_
43-14	6792-6797	every	_
43-15	6798-6802	pair	_
43-16	6803-6805	of	_
43-17	6806-6812	voxels	_
43-18	6813-6815	in	_
43-19	6816-6819	the	_
43-20	6820-6826	entire	_
43-21	6827-6832	brain	_
43-22	6833-6834	.	_

Text=Two voxels with a correlation coefficient, which was larger than a predefined threshold, were considered to be significantly connected.
44-1	6835-6838	Two	_
44-2	6839-6845	voxels	_
44-3	6846-6850	with	_
44-4	6851-6852	a	_
44-5	6853-6864	correlation	_
44-6	6865-6876	coefficient	_
44-7	6877-6878	,	_
44-8	6879-6884	which	_
44-9	6885-6888	was	_
44-10	6889-6895	larger	_
44-11	6896-6900	than	_
44-12	6901-6902	a	_
44-13	6903-6913	predefined	_
44-14	6914-6923	threshold	_
44-15	6924-6925	,	_
44-16	6926-6930	were	_
44-17	6931-6941	considered	_
44-18	6942-6944	to	_
44-19	6945-6947	be	_
44-20	6948-6961	significantly	_
44-21	6962-6971	connected	_
44-22	6972-6973	.	_

Text=To obtain reliable and robust results, we used multiple threshold levels (R = 0.4, 0.6 and 0.8) to compute the rsFCD.
45-1	6974-6976	To	_
45-2	6977-6983	obtain	_
45-3	6984-6992	reliable	_
45-4	6993-6996	and	_
45-5	6997-7003	robust	_
45-6	7004-7011	results	_
45-7	7012-7013	,	_
45-8	7014-7016	we	_
45-9	7017-7021	used	_
45-10	7022-7030	multiple	_
45-11	7031-7040	threshold	_
45-12	7041-7047	levels	_
45-13	7048-7049	(	_
45-14	7050-7051	R	_
45-15	7052-7053	=	_
45-16	7054-7057	0.4	_
45-17	7058-7059	,	_
45-18	7060-7063	0.6	_
45-19	7064-7067	and	_
45-20	7068-7071	0.8	_
45-21	7072-7073	)	_
45-22	7074-7076	to	_
45-23	7077-7084	compute	_
45-24	7085-7088	the	_
45-25	7089-7094	rsFCD	_
45-26	7095-7096	.	_

Text=The rsFCD calculation was restricted to a whole brain mask including the cerebellum.
46-1	7097-7100	The	_
46-2	7101-7106	rsFCD	_
46-3	7107-7118	calculation	_
46-4	7119-7122	was	_
46-5	7123-7133	restricted	_
46-6	7134-7136	to	_
46-7	7137-7138	a	_
46-8	7139-7144	whole	_
46-9	7145-7150	brain	_
46-10	7151-7155	mask	_
46-11	7156-7165	including	_
46-12	7166-7169	the	_
46-13	7170-7180	cerebellum	_
46-14	7181-7182	.	_

Text=The rsFCD at a given voxel x0 was computed as the total functional connectivity, k (x0), between x0 and all other voxels.
47-1	7183-7186	The	_
47-2	7187-7192	rsFCD	_
47-3	7193-7195	at	_
47-4	7196-7197	a	_
47-5	7198-7203	given	_
47-6	7204-7209	voxel	_
47-7	7210-7212	x0	_
47-8	7213-7216	was	_
47-9	7217-7225	computed	_
47-10	7226-7228	as	_
47-11	7229-7232	the	_
47-12	7233-7238	total	_
47-13	7239-7249	functional	_
47-14	7250-7262	connectivity	_
47-15	7263-7264	,	_
47-16	7265-7266	k	_
47-17	7267-7268	(	_
47-18	7269-7271	x0	_
47-19	7272-7273	)	_
47-20	7274-7275	,	_
47-21	7276-7283	between	_
47-22	7284-7286	x0	_
47-23	7287-7290	and	_
47-24	7291-7294	all	_
47-25	7295-7300	other	_
47-26	7301-7307	voxels	_
47-27	7308-7309	.	_

Text=This calculation was repeated for all voxels within the whole brain mask.
48-1	7310-7314	This	_
48-2	7315-7326	calculation	_
48-3	7327-7330	was	_
48-4	7331-7339	repeated	_
48-5	7340-7343	for	_
48-6	7344-7347	all	_
48-7	7348-7354	voxels	_
48-8	7355-7361	within	_
48-9	7362-7365	the	_
48-10	7366-7371	whole	_
48-11	7372-7377	brain	_
48-12	7378-7382	mask	_
48-13	7383-7384	.	_

Text=To increase the normality of the distribution, grand mean scaling was performed by dividing the rsFCD of each voxel by the mean value of the whole brain.
49-1	7385-7387	To	_
49-2	7388-7396	increase	_
49-3	7397-7400	the	_
49-4	7401-7410	normality	_
49-5	7411-7413	of	_
49-6	7414-7417	the	_
49-7	7418-7430	distribution	_
49-8	7431-7432	,	_
49-9	7433-7438	grand	_
49-10	7439-7443	mean	_
49-11	7444-7451	scaling	_
49-12	7452-7455	was	_
49-13	7456-7465	performed	_
49-14	7466-7468	by	_
49-15	7469-7477	dividing	_
49-16	7478-7481	the	_
49-17	7482-7487	rsFCD	_
49-18	7488-7490	of	_
49-19	7491-7495	each	_
49-20	7496-7501	voxel	_
49-21	7502-7504	by	_
49-22	7505-7508	the	_
49-23	7509-7513	mean	_
49-24	7514-7519	value	_
49-25	7520-7522	of	_
49-26	7523-7526	the	_
49-27	7527-7532	whole	_
49-28	7533-7538	brain	_
49-29	7539-7540	.	_

Text=Finally, the rsFCD maps were spatially smoothed using a 6 mm × 6 mm × 6 mm full-width at half maximum (FWHM) Gaussian kernel.
50-1	7541-7548	Finally	_
50-2	7549-7550	,	_
50-3	7551-7554	the	_
50-4	7555-7560	rsFCD	_
50-5	7561-7565	maps	_
50-6	7566-7570	were	_
50-7	7571-7580	spatially	_
50-8	7581-7589	smoothed	_
50-9	7590-7595	using	_
50-10	7596-7597	a	_
50-11	7598-7599	6	_
50-12	7600-7602	mm	_
50-13	7603-7604	×	_
50-14	7605-7606	6	_
50-15	7607-7609	mm	_
50-16	7610-7611	×	_
50-17	7612-7613	6	_
50-18	7614-7616	mm	_
50-19	7617-7627	full-width	_
50-20	7628-7630	at	_
50-21	7631-7635	half	_
50-22	7636-7643	maximum	_
50-23	7644-7645	(	_
50-24	7646-7650	FWHM	_
50-25	7651-7652	)	_
50-26	7653-7661	Gaussian	_
50-27	7662-7668	kernel	_
50-28	7669-7670	.	_

Text=Inter-group differences in rsFCD were voxel-wisely compared within a cerebellar mask using a general linear model with age and sex as nuisance variables.
51-1	7671-7682	Inter-group	_
51-2	7683-7694	differences	_
51-3	7695-7697	in	_
51-4	7698-7703	rsFCD	_
51-5	7704-7708	were	_
51-6	7709-7721	voxel-wisely	_
51-7	7722-7730	compared	_
51-8	7731-7737	within	_
51-9	7738-7739	a	_
51-10	7740-7750	cerebellar	_
51-11	7751-7755	mask	_
51-12	7756-7761	using	_
51-13	7762-7763	a	_
51-14	7764-7771	general	_
51-15	7772-7778	linear	_
51-16	7779-7784	model	_
51-17	7785-7789	with	_
51-18	7790-7793	age	_
51-19	7794-7797	and	_
51-20	7798-7801	sex	_
51-21	7802-7804	as	_
51-22	7805-7813	nuisance	_
51-23	7814-7823	variables	_
51-24	7824-7825	.	_

Text=Correction for multiple comparisons was performed using the voxel-level false discovery rate (FDR) method with a corrected threshold of P <0.05.
52-1	7826-7836	Correction	_
52-2	7837-7840	for	_
52-3	7841-7849	multiple	_
52-4	7850-7861	comparisons	_
52-5	7862-7865	was	_
52-6	7866-7875	performed	_
52-7	7876-7881	using	_
52-8	7882-7885	the	_
52-9	7886-7897	voxel-level	_
52-10	7898-7903	false	_
52-11	7904-7913	discovery	_
52-12	7914-7918	rate	_
52-13	7919-7920	(	_
52-14	7921-7924	FDR	_
52-15	7925-7926	)	_
52-16	7927-7933	method	_
52-17	7934-7938	with	_
52-18	7939-7940	a	_
52-19	7941-7950	corrected	_
52-20	7951-7960	threshold	_
52-21	7961-7963	of	_
52-22	7964-7965	P	_
52-23	7966-7967	<	_
52-24	7968-7972	0.05	_
52-25	7973-7974	.	_

Text=The significant regions in 3 comparisons (corresponding to the three thresholds) were overlapped.
53-1	7975-7978	The	_
53-2	7979-7990	significant	_
53-3	7991-7998	regions	_
53-4	7999-8001	in	_
53-5	8002-8003	3	_
53-6	8004-8015	comparisons	_
53-7	8016-8017	(	_
53-8	8018-8031	corresponding	_
53-9	8032-8034	to	_
53-10	8035-8038	the	_
53-11	8039-8044	three	_
53-12	8045-8055	thresholds	_
53-13	8056-8057	)	_
53-14	8058-8062	were	_
53-15	8063-8073	overlapped	_
53-16	8074-8075	.	_

Text=The overlapping areas were identified as the regions of interest (ROIs) for the correlation analyses and were defined as seed regions for the subsequent rsFC analyses.
54-1	8076-8079	The	_
54-2	8080-8091	overlapping	_
54-3	8092-8097	areas	_
54-4	8098-8102	were	_
54-5	8103-8113	identified	_
54-6	8114-8116	as	_
54-7	8117-8120	the	_
54-8	8121-8128	regions	_
54-9	8129-8131	of	_
54-10	8132-8140	interest	_
54-11	8141-8142	(	_
54-12	8143-8147	ROIs	_
54-13	8148-8149	)	_
54-14	8150-8153	for	_
54-15	8154-8157	the	_
54-16	8158-8169	correlation	_
54-17	8170-8178	analyses	_
54-18	8179-8182	and	_
54-19	8183-8187	were	_
54-20	8188-8195	defined	_
54-21	8196-8198	as	_
54-22	8199-8203	seed	_
54-23	8204-8211	regions	_
54-24	8212-8215	for	_
54-25	8216-8219	the	_
54-26	8220-8230	subsequent	_
54-27	8231-8235	rsFC	_
54-28	8236-8244	analyses	_
54-29	8245-8246	.	_

Text=The ROI-based correlation analyses with the clinical variables, including antipsychotic dosages of chlorpromazine equivalents, illness duration and PANSS scores, were performed for the patient group using partial correlation analysis with age and sex as the nuisance covariates.
55-1	8247-8250	The	_
55-2	8251-8260	ROI-based	_
55-3	8261-8272	correlation	_
55-4	8273-8281	analyses	_
55-5	8282-8286	with	_
55-6	8287-8290	the	_
55-7	8291-8299	clinical	_
55-8	8300-8309	variables	_
55-9	8310-8311	,	_
55-10	8312-8321	including	_
55-11	8322-8335	antipsychotic	_
55-12	8336-8343	dosages	_
55-13	8344-8346	of	_
55-14	8347-8361	chlorpromazine	_
55-15	8362-8373	equivalents	_
55-16	8374-8375	,	_
55-17	8376-8383	illness	_
55-18	8384-8392	duration	_
55-19	8393-8396	and	_
55-20	8397-8402	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
55-21	8403-8409	scores	_
55-22	8410-8411	,	_
55-23	8412-8416	were	_
55-24	8417-8426	performed	_
55-25	8427-8430	for	_
55-26	8431-8434	the	_
55-27	8435-8442	patient	_
55-28	8443-8448	group	_
55-29	8449-8454	using	_
55-30	8455-8462	partial	_
55-31	8463-8474	correlation	_
55-32	8475-8483	analysis	_
55-33	8484-8488	with	_
55-34	8489-8492	age	_
55-35	8493-8496	and	_
55-36	8497-8500	sex	_
55-37	8501-8503	as	_
55-38	8504-8507	the	_
55-39	8508-8516	nuisance	_
55-40	8517-8527	covariates	_
55-41	8528-8529	.	_

Text=For these correlation analyses, a significant threshold was set at P <0.05. rsFC analysis Most of the data preprocessing steps for the rsFC analysis were the same as the preprocessing steps for the rsFCD calculation.
56-1	8530-8533	For	_
56-2	8534-8539	these	_
56-3	8540-8551	correlation	_
56-4	8552-8560	analyses	_
56-5	8561-8562	,	_
56-6	8563-8564	a	_
56-7	8565-8576	significant	_
56-8	8577-8586	threshold	_
56-9	8587-8590	was	_
56-10	8591-8594	set	_
56-11	8595-8597	at	_
56-12	8598-8599	P	_
56-13	8600-8601	<	_
56-14	8602-8607	0.05.	_
56-15	8608-8612	rsFC	_
56-16	8613-8621	analysis	_
56-17	8622-8626	Most	_
56-18	8627-8629	of	_
56-19	8630-8633	the	_
56-20	8634-8638	data	_
56-21	8639-8652	preprocessing	_
56-22	8653-8658	steps	_
56-23	8659-8662	for	_
56-24	8663-8666	the	_
56-25	8667-8671	rsFC	_
56-26	8672-8680	analysis	_
56-27	8681-8685	were	_
56-28	8686-8689	the	_
56-29	8690-8694	same	_
56-30	8695-8697	as	_
56-31	8698-8701	the	_
56-32	8702-8715	preprocessing	_
56-33	8716-8721	steps	_
56-34	8722-8725	for	_
56-35	8726-8729	the	_
56-36	8730-8735	rsFCD	_
56-37	8736-8747	calculation	_
56-38	8748-8749	.	_

Text=The only difference was that functional images were smoothed using a Gaussian kernel of 6 mm × 6 mm × 6 mm FWHM after normalization.
57-1	8750-8753	The	_
57-2	8754-8758	only	_
57-3	8759-8769	difference	_
57-4	8770-8773	was	_
57-5	8774-8778	that	_
57-6	8779-8789	functional	_
57-7	8790-8796	images	_
57-8	8797-8801	were	_
57-9	8802-8810	smoothed	_
57-10	8811-8816	using	_
57-11	8817-8818	a	_
57-12	8819-8827	Gaussian	_
57-13	8828-8834	kernel	_
57-14	8835-8837	of	_
57-15	8838-8839	6	_
57-16	8840-8842	mm	_
57-17	8843-8844	×	_
57-18	8845-8846	6	_
57-19	8847-8849	mm	_
57-20	8850-8851	×	_
57-21	8852-8853	6	_
57-22	8854-8856	mm	_
57-23	8857-8861	FWHM	_
57-24	8862-8867	after	_
57-25	8868-8881	normalization	_
57-26	8882-8883	.	_

Text=For each subject, Pearson ’ s correlation coefficients between the mean time series of the seed region and that of each voxel in the whole brain was computed and converted to z-values using Fisher ’ s r-to-z transformation to improve the normality.
58-1	8884-8887	For	_
58-2	8888-8892	each	_
58-3	8893-8900	subject	_
58-4	8901-8902	,	_
58-5	8903-8910	Pearson	_
58-6	8911-8912	’	_
58-7	8913-8914	s	_
58-8	8915-8926	correlation	_
58-9	8927-8939	coefficients	_
58-10	8940-8947	between	_
58-11	8948-8951	the	_
58-12	8952-8956	mean	_
58-13	8957-8961	time	_
58-14	8962-8968	series	_
58-15	8969-8971	of	_
58-16	8972-8975	the	_
58-17	8976-8980	seed	_
58-18	8981-8987	region	_
58-19	8988-8991	and	_
58-20	8992-8996	that	_
58-21	8997-8999	of	_
58-22	9000-9004	each	_
58-23	9005-9010	voxel	_
58-24	9011-9013	in	_
58-25	9014-9017	the	_
58-26	9018-9023	whole	_
58-27	9024-9029	brain	_
58-28	9030-9033	was	_
58-29	9034-9042	computed	_
58-30	9043-9046	and	_
58-31	9047-9056	converted	_
58-32	9057-9059	to	_
58-33	9060-9068	z-values	_
58-34	9069-9074	using	_
58-35	9075-9081	Fisher	_
58-36	9082-9083	’	_
58-37	9084-9085	s	_
58-38	9086-9092	r-to-z	_
58-39	9093-9107	transformation	_
58-40	9108-9110	to	_
58-41	9111-9118	improve	_
58-42	9119-9122	the	_
58-43	9123-9132	normality	_
58-44	9133-9134	.	_

Text=Next, the individual ’ s z-values were entered into a random-effects one-sample t-test in a voxel-wise manner using SPM8.
59-1	9135-9139	Next	_
59-2	9140-9141	,	_
59-3	9142-9145	the	_
59-4	9146-9156	individual	_
59-5	9157-9158	’	_
59-6	9159-9160	s	_
59-7	9161-9169	z-values	_
59-8	9170-9174	were	_
59-9	9175-9182	entered	_
59-10	9183-9187	into	_
59-11	9188-9189	a	_
59-12	9190-9204	random-effects	_
59-13	9205-9215	one-sample	_
59-14	9216-9222	t-test	_
59-15	9223-9225	in	_
59-16	9226-9227	a	_
59-17	9228-9238	voxel-wise	_
59-18	9239-9245	manner	_
59-19	9246-9251	using	_
59-20	9252-9256	SPM8	_
59-21	9257-9258	.	_

Text=FDR correction with P <0.05 was used to identify brain regions that showed significant positive correlations with the seed region.
60-1	9259-9262	FDR	_
60-2	9263-9273	correction	_
60-3	9274-9278	with	_
60-4	9279-9280	P	_
60-5	9281-9282	<	_
60-6	9283-9287	0.05	_
60-7	9288-9291	was	_
60-8	9292-9296	used	_
60-9	9297-9299	to	_
60-10	9300-9308	identify	_
60-11	9309-9314	brain	_
60-12	9315-9322	regions	_
60-13	9323-9327	that	_
60-14	9328-9334	showed	_
60-15	9335-9346	significant	_
60-16	9347-9355	positive	_
60-17	9356-9368	correlations	_
60-18	9369-9373	with	_
60-19	9374-9377	the	_
60-20	9378-9382	seed	_
60-21	9383-9389	region	_
60-22	9390-9391	.	_

Text=Next, a two-sample t-test was performed within the positive rs-FC mask to quantitatively compare the differences in rsFC of the seed region between schizophrenia patients and healthy controls.
61-1	9392-9396	Next	_
61-2	9397-9398	,	_
61-3	9399-9400	a	_
61-4	9401-9411	two-sample	_
61-5	9412-9418	t-test	_
61-6	9419-9422	was	_
61-7	9423-9432	performed	_
61-8	9433-9439	within	_
61-9	9440-9443	the	_
61-10	9444-9452	positive	_
61-11	9453-9458	rs-FC	_
61-12	9459-9463	mask	_
61-13	9464-9466	to	_
61-14	9467-9481	quantitatively	_
61-15	9482-9489	compare	_
61-16	9490-9493	the	_
61-17	9494-9505	differences	_
61-18	9506-9508	in	_
61-19	9509-9513	rsFC	_
61-20	9514-9516	of	_
61-21	9517-9520	the	_
61-22	9521-9525	seed	_
61-23	9526-9532	region	_
61-24	9533-9540	between	_
61-25	9541-9554	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
61-26	9555-9563	patients	_
61-27	9564-9567	and	_
61-28	9568-9575	healthy	_
61-29	9576-9584	controls	_
61-30	9585-9586	.	_

Text=Multiple comparisons were corrected using the FDR method with a corrected threshold of P <0.05.
62-1	9587-9595	Multiple	_
62-2	9596-9607	comparisons	_
62-3	9608-9612	were	_
62-4	9613-9622	corrected	_
62-5	9623-9628	using	_
62-6	9629-9632	the	_
62-7	9633-9636	FDR	_
62-8	9637-9643	method	_
62-9	9644-9648	with	_
62-10	9649-9650	a	_
62-11	9651-9660	corrected	_
62-12	9661-9670	threshold	_
62-13	9671-9673	of	_
62-14	9674-9675	P	_
62-15	9676-9677	<	_
62-16	9678-9682	0.05	_
62-17	9683-9684	.	_

Text=To test the association between rsFC and the clinical variables, voxel-wise multiple regression analysis was performed for the patient group within a mask constructed from the group differences between patients and controls.
63-1	9685-9687	To	_
63-2	9688-9692	test	_
63-3	9693-9696	the	_
63-4	9697-9708	association	_
63-5	9709-9716	between	_
63-6	9717-9721	rsFC	_
63-7	9722-9725	and	_
63-8	9726-9729	the	_
63-9	9730-9738	clinical	_
63-10	9739-9748	variables	_
63-11	9749-9750	,	_
63-12	9751-9761	voxel-wise	_
63-13	9762-9770	multiple	_
63-14	9771-9781	regression	_
63-15	9782-9790	analysis	_
63-16	9791-9794	was	_
63-17	9795-9804	performed	_
63-18	9805-9808	for	_
63-19	9809-9812	the	_
63-20	9813-9820	patient	_
63-21	9821-9826	group	_
63-22	9827-9833	within	_
63-23	9834-9835	a	_
63-24	9836-9840	mask	_
63-25	9841-9852	constructed	_
63-26	9853-9857	from	_
63-27	9858-9861	the	_
63-28	9862-9867	group	_
63-29	9868-9879	differences	_
63-30	9880-9887	between	_
63-31	9888-9896	patients	_
63-32	9897-9900	and	_
63-33	9901-9909	controls	_
63-34	9910-9911	.	_

Text=A threshold of P <0.01 was considered significant.
64-1	9912-9913	A	_
64-2	9914-9923	threshold	_
64-3	9924-9926	of	_
64-4	9927-9928	P	_
64-5	9929-9930	<	_
64-6	9931-9935	0.01	_
64-7	9936-9939	was	_
64-8	9940-9950	considered	_
64-9	9951-9962	significant	_
64-10	9963-9964	.	_

